drugset / Trial / NCT01316380

Efficacy and Safety of 2 Doses of Tiotropium Via Respimat in Adult Patients With Mild Persistent Asthma

NCT01316380

Phase 3 Completed 465 enrolled Boehringer Ingelheim Pfizer · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

The aim of this trial is to evaluate the efficacy and safety of 2.5 and 5 mcg tiotropium compared to placebo over 12 week treatment period. Tiotropium inhalation solution will be delivered via Respimat inhaler and will be examined on top of maintenance inhaled corticosteroid treatment in patients with mild persistent asthma. Efficacy and safety will be assessed by measuring the effects on lung functions, effects on lung exacerbations, effects on asthma control and numbers of adverse events.

Timeline

Start
2011-03
Primary completion
2012-04
Completion
2012-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Tiotropium Other / unclassified 2.5 ug Inhaled
Subject Tiotropium Other / unclassified 5 ug Inhaled

Indications